From GlobeNewswire: 2025-04-29 09:25:00

Fate Therapeutics, Inc. announced five presentations of clinical and preclinical data at the ASGCT 28th Annual Meeting. The company will discuss data from their Phase 1 clinical trial of FT522, an off-the-shelf, CD19-targeted CAR NK cell product candidate for B-cell lymphoma. In addition, they will present preclinical data from their CAR T-cell product platform for various indications. The presentations will showcase the company’s iPSC product platform, which uses human induced pluripotent stem cells for creating engineered cell products. Fate Therapeutics aims to bring iPSC-derived cellular immunotherapies to patients with cancer and autoimmune diseases.

The oral presentation will focus on an off-the-shelf CAR NK cell with Alloimmune Defense Technology, while poster presentations will cover topics like promoting functional persistence of allogeneic cell therapies and targeting UPAR with CAR T cells. These presentations aim to highlight the potential of Fate Therapeutics’ iPSC product platform in providing innovative solutions for various diseases. The company’s approach involves engineering master iPSC lines to create uniform and well-defined cell products that can be readily available for patients without the need for conditioning chemotherapy.



Read more at GlobeNewswire: Fate Therapeutics Announces Five Presentations on